Background: Lacosamide and levetiracetam are antiseizure medications (ASMs) commonly utilized in the treatment and prevention of seizures. Historically, these agents have been administered as slow IV infusions after further dilution. Recent literature suggests that rapid administration via undiluted IV push may be safe and may increase efficiency of administration. Objective: This study aimed to evaluate the safety and tolerability of undiluted IV push lacosamide and levetiracetam over 5 min. Methods: This study was conducted as a single-centered, retrospective, observational cohort that analyzed the rapid administration of undiluted lacosamide and levetiracetam. Adult patients admitted from September 1st, 2019, to May 31st, 2020, receiving at least one administration of IV push lacosamide at any dose or levetiracetam at doses ≤ 1500 mg were evaluated. The primary safety outcomes were the incidence of hypotension and bradycardia. Results: A total of 86 subjects were evaluated; 36 patients were administered lacosamide, and 50 patients were administered levetiracetam. Hypotension or bradycardia occurred in 6 patients in the lacosamide group (16.6%) and 6 patients in the levetiracetam group (12.0%). There were no reported infusion site reactions. Among the subjects who received lacosamide and had a 12-lead electrocardiogram (EKG), there were no reported incidences of a prolonged PR interval. Conclusions: In this safety-analysis cohort, undiluted lacosamide and levetiracetam were not associated with significant adverse events when administered via IV push over 5 min. This seems to be a safe alternative method of administration to intermittent infusion. A larger, prospective cohort is needed to confirm these findings.
Abou-KhalilB. Levetiracetam in the treatment of epilepsy. Neuropsychiatric Dis Treat. 2008;4(3):507-523. doi:10.2147/ndt.s2937.
2.
KellinghausC. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Therapeut Clin Risk Manag. 2009;5:757-766. doi:10.2147/tcrm.s5189.
DavidsonKENewellJAlsherbiniKKrushinskiJJonesGM. Safety and efficiency of intravenous push lacosamide administration. Neurocritical Care. 2018;29(3):491-495. doi:10.1007/s12028-018-0560-6.
6.
McLaughlinKCarabettaSHuntN, et al.Safety of intravenous push lacosamide compared with intravenous piggyback at a tertiary academic medical center. Ann Pharmacother. 2021;55(2):181-186. doi:10.1177/1060028020943569.
7.
BurakgaziEBashirSDossVPellockJ. The safety and tolerability of different intravenous administrations of levetiracetam, bolus versus infusion, in intensive care unit patients. Clin EEG Neurosci. 2014;45(2):89-91. doi:10.1177/1550059413496777.
8.
MorganOMedenwaldB. Safety and tolerability of rapid administration undiluted levetiracetam. Neurocritical Care. 2020;32(1):131-134. doi:10.1007/s12028-019-00708-5.
9.
WhelessJWClarkeDHovingaCA, et al.Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: A safety study. J Child Neurol. 2009;24(8):946-951. doi:10.1177/0883073808331351.
10.
KellinghausCBerningSImmischI, et al.Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand. 2011;123(2):137-141. doi:10.1111/j.1600-0404.2010.01423.x.
11.
KapurJElmJChamberlainJM, et al.Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381(22):2103-2113. doi:10.1056/NEJMoa1905795.
12.
Der-NigoghossianCRubinosCAlkhachroumAClaassenJ. Status epilepticus - time is brain and treatment considerations. Curr Opin Crit Care. 2019;25(6):638-646. doi:10.1097/MCC.0000000000000661.
13.
GlauserTShinnarSGlossD, et al.Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American epilepsy society. Epilepsy Current. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48.
14.
HallerJTBonninSRadosevichJ. Rapid Administration of Undiluted Intravenous Levetiracetam, Epilepsia. 62; 2021:1865-1870. Jun 24Online ahead of print. 10.1111/epi.16961.
